Citius Pharmaceuticals, Inc. (CTXR) stock
CTXRNasdaqPharmaceutical PreparationsFiscal year ends September 30
$0.53−0.01 (-1.40%)
Close on Nov 16, 2026Market cap $14.48MP/E –Yield –
Citius Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Citius Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.93M, down 43.2% year over year. For fiscal 2025 it was $9.16M, down 23.1% from the year before. The highest annual figure on record is $17.66M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $9.16M | -23.1% |
| FY2024 | Sep 30, 2024 | $11.91M | -19.7% |
| FY2023 | Sep 30, 2023 | $14.82M | -16.1% |
| FY2022 | Sep 30, 2022 | $17.66M | +44.2% |
| FY2021 | Sep 30, 2021 | $12.24M | +38.9% |
| FY2020 | Sep 30, 2020 | $8.81M | +6950.2% |
| FY2019 | Sep 30, 2019 | $125.00K | -98.1% |
| FY2018 | Sep 30, 2018 | $6.56M | +123.5% |
| FY2017 | Sep 30, 2017 | $2.94M | +0.1% |
| FY2016 | Sep 30, 2016 | $2.93M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $1.05M | -35.0% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $1.63M | -56.6% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $1.60M | -24.8% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $1.64M | -43.7% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $1.62M | -41.3% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $3.77M | +4.5% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $2.13M | -18.9% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $2.91M | +1.1% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $2.76M | -19.8% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $3.61M | -6.5% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $2.62M | -46.4% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $2.88M | -16.5% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $3.45M | -36.9% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $3.86M | +68.1% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $4.89M | +121.8% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $3.45M | +122.5% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $5.46M | -11.8% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $2.29M | +54.2% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $2.20M | -16.7% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $1.55M | -23.0% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $6.19M | +132.4% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $1.49M | -26.2% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $2.64M | -4.4% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $2.02M | +18.6% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $2.66M | +26.1% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $2.02M | +16.1% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $2.77M | +255.2% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $1.70M | -50.6% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $2.11M | +248.4% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $1.74M | +266.2% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $778.86K | +308.5% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $3.44M | +300.0% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $606.52K | -57.0% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $474.53K | -75.3% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $190.65K | -50.0% |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $859.92K | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $1.41M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $1.92M | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | $381.12K | – |
See a number that looks wrong?